1 North Waukegan Road
At AbbVie, we strive to discover and develop medicines that deliver transformational improvements in cancer treatment by uniquely combining our deep knowledge in core areas of biology with cutting-edge technologies, and by working together with our partners – scientists, clinical experts, industry peers, advocates, and patients. We remain focused on delivering these transformative advances in treatment across some of the most debilitating and widespread cancers. We are also committed to exploring solutions to help patients obtain access to our cancer medicines. With the acquisitions of Pharmacyclics in 2015 and Stemcentrx in 2016, our research and development efforts, and through collaborations, AbbVie's oncology portfolio now consists of marketed medicines and a pipeline containing multiple new molecules being evaluated worldwide in more than 200 clinical trials and more than 20 different tumor types. For more information, please visit http://abbvieoncology.com.
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
1500 Seaport Blvd., Redwood City, CA
200 Sidney St, Cambridge, MA 02139
100 Research Drive, Worcester, MA 01605
CEO: Richard A. Gonzalez
CFO: William J. Chase
Please click here for clinical trial information..
Tweets by AbbVie
Determined to Make a Difference
637 articles with AbbVie
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan.
AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
First of two pivotal Phase 3 studies met primary efficacy endpoint and all ranked secondary endpoints
AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint.
AbbVie and Voyager Therapeutics inked a collaboration deal to develop treatments for Alzheimer’s disease and other neurodegenerative diseases.
AbbVie today presented new positive results from a Phase 2b dose-ranging study evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis.
AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab...
2/19/2018AbbVie presented today new positive results from the pivotal Phase 3 ultIMMa-1 and ultIMMa-2 replicate clinical trials that evaluated the safety and efficacy of risankizumab (150 mg) compared to placebo or ustekinumab (45 or 90 mg, based on patient weight).
2/12/2018A look at three drug approvals of vital importance to the company this year.
2/12/2018A look at a few bargains in today's choppy market.
AbbVie and MBC BioLabs announced that they have teamed up to help support and mentor promising startups.
With the additional space, AbbVie will hire 15 new employees.
Sometimes the biggest are also the best. That's the case for biotherapeutics stocks.
1/31/2018The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash.
A look at three big biotech companies that have big catalysts this year that could have a, you guessed it, big effect.
AbbVie provided an unexpectedly strong 2018 guidance revision, largely built on the new corporate tax rate.
This is a market like the world has never seen.
AbbVie announced financial results for the fourth quarter ended December 31, 2017.
AbbVie will announce its fourth-quarter 2017 financial results on Friday, Jan. 26, 2018, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time.
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
AbbVie today announced the FDA granted Breakthrough Therapy Designation for the investigational, once-daily oral JAK1-selective inhibitor upadacitinib in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.